By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Diepenbeek      Belgium
Phone: n/a Fax: n/a



Company News
Apitope Announces Enrolment Of First Patient In Phase I Trial Of ATX-GD-59 For The Treatment Of Graves' Disease 10/26/2016 6:44:58 AM
Merck KGaA (MKGAF.PK) Hands Back Novel Multiple Sclerosis Drug to Apitope 10/17/2016 7:54:30 AM
Apitope Raises €12 Million In Series B Funding To Progress Treatments For Autoimmune Diseases 9/29/2015 6:26:48 AM
Apitope Announces Completion Of Enrolment In Phase IIA Clinical Trial Of ATX-MS-1467 In Relapsing Multiple Sclerosis 8/6/2015 8:50:47 AM
Apitope Release: FDA Grants Orphan Status For ATX-F8-117 For The Treatment Of Haemophilia A Patients In The U.S. 6/9/2015 9:19:15 AM
Abzena To Provide Apitope With Analytical Support For Development Of A Novel Treatment For Factor VIII Inhibitors In Haemophilia A Patients 5/19/2015 10:58:23 AM
Apitope Receives Orphan Designation In The European Union For ATX-F8-117 For The Treatment Of Haemophilia A 11/25/2014 10:24:09 AM
Apitope Treatment Approach Published In Nature Communications 9/4/2014 10:03:42 AM
Apitope Progresses Graves' Disease Treatment 6/19/2014 6:28:29 AM
Apitope Initiates Preclinical Development Of Peptide Therapy, ATX-F8-117, To Treat Factor VIII Intolerance 5/7/2014 9:52:50 AM